<DOC>
	<DOCNO>NCT00010231</DOCNO>
	<brief_summary>RATIONALE : Combining calcitriol dexamethasone may increase effectiveness therapy make cancer cell sensitive dexamethasone . PURPOSE : Phase I trial study effectiveness calcitriol combine dexamethasone treat patient prostate cancer respond previous hormone therapy .</brief_summary>
	<brief_title>Calcitriol Plus Dexamethasone Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose calcitriol administer alone combination dexamethasone patient hormone-refractory prostate cancer . - Determine pharmacokinetics calcitriol without dexamethasone patient . OUTLINE : This dose-escalation study calcitriol . In first stage study , cohorts 3-6 patient receive escalate dos oral calcitriol day 1-3 . Dose escalation continue maximum tolerate dose ( MTD ) determine . In second stage , patient receive escalate dos oral calcitriol day 1-3 fixed dose oral dexamethasone day 0-4 . Treatment continue weekly absence disease progression unacceptable toxicity . Dose escalation continue MTD determine . Six additional patient may receive calcitriol dexamethasone one dose level MTD determine second stage , confirm MTD . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate progress regional metastatic disease despite primary hormonal therapy ( bilateral orchiectomy , estrogen , luteinizing hormonereleasing hormone ( LHRH ) therapy without simultaneous antiandrogen ) Documented new lesion rise PSA ( least 50 % increase 3 measurement 2 week apart ) prior antiandrogen progestational agent , hormonal agent cessation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT le 4 time upper limit normal Renal : Creatinine great 1.8 mg/dL Other : No uncontrolled diabetes mellitus Fertile patient must use effective double barrier contraception least 1 week , , least 2 week study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent epoetin alfa anemia allow Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics At least 28 day since prior antiandrogens progestational agent Concurrent testicular androgen suppression LHRH analog ( leuprolide goserelin ) allow nonorchidectomized patient Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>